# Calderasib PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/calderasib

> The next catalyst for calderasib, sponsored by Merck & Co., Inc. (MRK), is its topline data readout, Mar to Jun 2029.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | calderasib |
| Codes | MK-1084 |
| Sponsor | Merck & Co., Inc. (MRK) https://sec-api.dev/companies/mrk/catalysts |
| Indications | Colon Adenocarcinoma, [Non-small Cell Lung Cancer](https://sec-api.dev/indications/non-small-cell-lung-cancer) |
| Modality | small_molecule |
| FDA designations | breakthrough |

## Timeline

### Mar to Jun 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Colon Adenocarcinoma; Rectal Adenocarcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06997497 (A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-28 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06997497

### March 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Colon Adenocarcinoma; Rectal Adenocarcinoma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06997497 (A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-28 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06997497

### Dec 2029 to Mar 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Non-small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07190248 (A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-07 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT07190248

### December 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Non-small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07190248 (A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-07 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT07190248

## Same indication

- [Datopotamab deruxtecan](https://sec-api.dev/pdufa/datopotamab-deruxtecan) (AZN)
- [Fianlimab](https://sec-api.dev/pdufa/fianlimab) (REGN)
- [LBL-007](https://sec-api.dev/pdufa/lbl-007) (ONC)
- [Opdivo® (nivolumab)](https://sec-api.dev/pdufa/nivolumab) (BMY)
- [Tagrisso® (osimertinib)](https://sec-api.dev/pdufa/osimertinib) (AZN)
- [Pumitamig](https://sec-api.dev/pdufa/pumitamig) (BMY)
- [Sacituzumab govitecan-hziy (sg)](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy-sg) (GILD)
- [ORPATHYS® (savolitinib)](https://sec-api.dev/pdufa/savolitinib) (HCM)
- [LUMYKRAS™ (sotorasib)](https://sec-api.dev/pdufa/sotorasib) (AMGN)
- [Telisotuzumab vedotin](https://sec-api.dev/pdufa/telisotuzumab-vedotin) (ABBV)
- [TEVIMBRA® (tislelizumab)](https://sec-api.dev/pdufa/tislelizumab) (ONC)
- [Volrustomig](https://sec-api.dev/pdufa/volrustomig) (AZN)
- [YuTuo (zimberelimab)](https://sec-api.dev/pdufa/zimberelimab) (GILD)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/calderasib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Calderasib PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/calderasib

```bibtex
@misc{secapidev_pdufa_calderasib_20261116,
  title        = {Calderasib PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/calderasib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_calderasib_20261116","title":"Calderasib PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/calderasib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
